Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America

• Effectiveness of Niaspan [ Time Frame: every 4 to 8 weeks for 24 weeks ] [ Designated as safety issue: No ]
  Increasing serum HDL-C (high-density lipoprotein - cholesterol) levels
  
  

• Evaluate changes induced by Niaspan at the completion of the study against base line values [ Time Frame: every 4 to 8 weeks for 24 weeks ] [ Designated as safety issue: No ]
  Evaluation of changes in non-HDL-C (non-high-density lipoproteins-cholesterol) lipids, LDL- C (low-density lipoproteins-cholesterol), total cholesterol and triglycerides (including in subjects with high triglycerides 200 mg/dL), and the impact on the Framingham score
  
  
• Frequency of flushing events [ Time Frame: every 4 weeks for 24 weeks ] [ Designated as safety issue: Yes ]
  evaluate occurrence of such events over time
  
  
• Overall safety and tolerability of Niaspan [ Time Frame: every 4 weeks for 24 weeks ] [ Designated as safety issue: Yes ]
  Evaluate overall safety of Niaspan through evaluation of adverse events
  
  

This is a Post-Marketing Observational study (PMOS) of Niaspan® tablet in accordance with each country regulations. This study will be conducted in a prospective, single-arm, multi-center format. As this study is observational in nature, the follow-up of subject's is not prescriptive in nature and is according to the judgment of the physician (investigator in the course of treatment for each patient), within the period of 12 months. This includes an enrollment period of 6 months and a treatment duration in which each subject will be observed for approximately 6 months. Examinations, diagnostic measures, findings and observations performed as per usual medical practice during the observation period will be recorded on CRFs by the investigator or site staffs according to the protocol.

Prior to enrollment in the study, each subject will be required to give their written informed consent to participate in the study. Written informed consent will include a statement authorizing the use and/or disclosure of their personal and/or health data. The subject will be assured that patient confidentiality will be maintained at all times according to the local regulations, and that data that might identify the patient will not be collected

For patient's consenting to participate in this PMOS study and meeting all of the inclusion and none of the exclusion criteria, at the initial visit or baseline as well at subsequent visits if appropriate , their demographic, medical history, physical examination, vital sign, flushing/adverse event assessments, concomitant medication information, Niaspan dose change/compliance, and lab testing will be documented as per standard medical practice in each country, although not in a protocolized manner.

If Niaspan® treatment is discontinued, subjects will be followed for another 1 month for any adverse event.